CPX-351 (Cytarabine và Daunorubicin dạng liposome) so với venetoclax cộng với thuốc ức chế methyl hóa ở bệnh nhân mắc bệnh bạch cầu myeloid cấp tính mới được chẩn đoán: so sánh hồi cứu trên 600 bệnh nhân tại Mayo Clinic | Tạp chí Ung thư máu – Nature
CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving…
Noi dung day du cua bai viet
The comparative value of liposomal cytarabine/daunorubicin (CPX-351) versus venetoclax plus a hypomethylating agent (Ven-HMA) in the frontline treatment of older adults with primary (de novo) or secondary acute myeloid leukemia (AML) remains uncertain. In the current study, we retrospectively examined outcomes of 600 patients with newly diagnosed AML treated with CPX-351 (N = 112) or Ven-HMA (N = 488). AML subtypes included de novo (N = 277,46%), post-myelodysplastic syndrome (post-MDS, N = 114,19%), post-myeloproliferative neoplasm (post-MPN, N = 70,12%), post-MDS/MPN (N = 36,6%), and t-AML (N = 103,17%). Patients receiving CPX-351 were younger (median 65 vs. 73 years; p
Sản phẩm liên quan đến bài viết
Các sản phẩm này được tự động đối chiếu từ tiêu đề, tóm tắt và nội dung bài viết.
Câu hỏi thường gặp
Which products are related to this article?
The system matched these relevant products from the article content: Lucius Venetoclax – Mua trực tuyến VECLADX Venetoclax 100mg.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.